RNS Number : 7642H
  Osmetech PLC
  10 November 2008
   


    10 November 2008        
            
    Osmetech plc ('Osmetech' or the 'Company')

    Clinical trials commence for extended warfarin sensitivity test

    Osmetech plc (OMH.L), the international molecular diagnostics company announces that it has now commenced clinical trials for an
extended warfarin sensitivity test.  

    Osmetech obtained clearance from the US Food and Drug Administration (FDA) in July 2008 for its eSensor� Warfarin Sensitivity Test to be
used as an aid in the identification of patients at risk for increased sensitivity to the widely used blood-thinning drug, warfarin. The new
extended warfarin test incorporates a number of additional markers, including the CYP450 4F2 biomarker exclusively-licensed from Marshfield
Clinic. 

    Following successful pre-clinical studies, clinical trials will be conducted at three sites with the results supporting the Company's
submission for 510(k) clearance to the FDA expected to be filed before the end of 2008 as previously disclosed.

    James White, Chief Executive, Osmetech plc, said:

    "We are excited by the prospects of being able to provide what we believe will be the most comprehensive FDA-cleared test for warfarin
sensitivity available in the marketplace, which will include our important and unique biomarker, 4F2."



    Osmetech plc                                              +44 (0) 207 849 6027
    James White, Chief Executive Officer
    David Sandilands, Chief Financial Officer

    Madano Partnership                                  +44 (0) 207 593 4000
    Matthew Moth, Mark Way
    www.madano.com

    Canacccord Adams Limited                    +44 (0) 207 050 6500
    Robert Finlay


    About Osmetech plc
    (www.osmetech.com)

    Osmetech plc is an AIM-listed public company on the London Stock Exchange. The Company is a fast developing, international diagnostics
business with operations in Boston and Pasadena in the US, serving the high growth molecular diagnostic market targeting hospitals and
reference laboratories. 

    Osmetech has a strong portfolio of over 200 issued and pending patents and has launched its first generation eSensor 4800 platform, an
electrochemistry-based array system, together with an FDA cleared in vitro diagnostic test for Cystic Fibrosis carrier detection. 

    Osmetech's second generation platform, the eSensor XT-8 received FDA 510(k) clearance in July 2008 together with our eSensor Warfarin
Sensitivity Test. These products are now being marketed in the U.S. together with our 2C9 Genotyping Test for the drug metabolism gene,
CYP450 2C9, which is available for research use purposes only. 

    The eSensor XT-8 System is designed to support a broad menu of tests and Osmetech has scheduled for commercial launch a number of
further tests including: extended warfarin panel with our proprietary 4F2 marker, Cystic Fibrosis, venous thrombosis (Factor II, Factor V
Leiden and MTHFR) and the RESPLEX II respiratory pathogen assay recently in-licensed from Qiagen. The System provides accurate results while
minimizing technician involvement and we believe that its features compare favorably to those of other molecular detection systems. Its ease
of use, readily interpretable results, speed and low maintenance are particularly suited to the needs of the decentralizing market. 




This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
MSCEAXFXEDDPFFE
Osmetech (LSE:OMH)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Osmetech Charts.
Osmetech (LSE:OMH)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Osmetech Charts.